Fusion Antibodies Past Earnings Performance
Past criteria checks 0/6
Fusion Antibodies's earnings have been declining at an average annual rate of -19.2%, while the Life Sciences industry saw earnings growing at 16% annually. Revenues have been declining at an average rate of 7.6% per year.
Key information
-19.2%
Earnings growth rate
-6.9%
EPS growth rate
| Life Sciences Industry Growth | 36.9% |
| Revenue growth rate | -7.6% |
| Return on equity | -124.1% |
| Net Margin | -196.0% |
| Next Earnings Update | 12 Sep 2024 |
Recent past performance updates
Recent updates
Here's Why We're Not At All Concerned With Fusion Antibodies' (LON:FAB) Cash Burn Situation
Aug 31
Here's Why We're Not Too Worried About Fusion Antibodies' (LON:FAB) Cash Burn Situation
Jan 25We Think Fusion Antibodies (LON:FAB) Can Easily Afford To Drive Business Growth
May 09Investors Who Bought Fusion Antibodies (LON:FAB) Shares A Year Ago Are Now Up 146%
Mar 17Companies Like Fusion Antibodies (LON:FAB) Can Afford To Invest In Growth
Jan 04Revenue & Expenses Breakdown
How Fusion Antibodies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1 | -2 | 2 | 0 |
| 31 Dec 23 | 1 | -3 | 3 | 0 |
| 30 Sep 23 | 2 | -3 | 3 | 0 |
| 30 Jun 23 | 2 | -3 | 3 | 0 |
| 31 Mar 23 | 3 | -3 | 3 | 0 |
| 31 Dec 22 | 4 | -2 | 3 | 0 |
| 30 Sep 22 | 4 | -2 | 3 | 0 |
| 30 Jun 22 | 5 | -1 | 3 | 0 |
| 31 Mar 22 | 5 | -1 | 3 | 0 |
| 31 Dec 21 | 5 | -2 | 3 | 0 |
| 30 Sep 21 | 5 | -3 | 3 | 0 |
| 30 Jun 21 | 4 | -3 | 3 | 0 |
| 31 Mar 21 | 4 | -3 | 3 | 0 |
| 31 Dec 20 | 4 | -2 | 2 | 0 |
| 30 Sep 20 | 4 | -1 | 2 | 0 |
| 30 Jun 20 | 4 | -1 | 2 | 0 |
| 31 Mar 20 | 4 | -1 | 2 | 0 |
| 31 Dec 19 | 4 | -1 | 2 | 0 |
| 30 Sep 19 | 3 | -1 | 2 | 0 |
| 30 Jun 19 | 3 | -1 | 2 | 0 |
| 31 Mar 19 | 2 | -1 | 2 | 0 |
| 31 Dec 18 | 2 | -1 | 2 | 0 |
| 30 Sep 18 | 2 | -1 | 2 | 0 |
| 30 Jun 18 | 2 | -1 | 2 | 0 |
| 31 Mar 18 | 3 | -1 | 1 | 0 |
| 31 Mar 17 | 2 | 0 | 1 | 0 |
| 31 Mar 16 | 1 | 1 | 1 | 0 |
| 31 Mar 14 | 1 | 0 | 0 | 0 |
Quality Earnings: FAB is currently unprofitable.
Growing Profit Margin: FAB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FAB is unprofitable, and losses have increased over the past 5 years at a rate of 19.2% per year.
Accelerating Growth: Unable to compare FAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FAB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-13%).
Return on Equity
High ROE: FAB has a negative Return on Equity (-124.15%), as it is currently unprofitable.